<SEC-DOCUMENT>0001140361-25-000655.txt : 20250108
<SEC-HEADER>0001140361-25-000655.hdr.sgml : 20250108
<ACCEPTANCE-DATETIME>20250108183612
ACCESSION NUMBER:		0001140361-25-000655
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250108

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DarioHealth Corp.
		CENTRAL INDEX KEY:			0001533998
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				452973162
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88306
		FILM NUMBER:		25519609

	BUSINESS ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		972-4-770-6377

	MAIL ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LabStyle Innovations Corp.
		DATE OF NAME CHANGE:	20111101

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Titan Trust 2024 I
		CENTRAL INDEX KEY:			0002050526
		ORGANIZATION NAME:           	
		IRS NUMBER:				996319820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		WILMINGTON SAVINGS FUND SOCIETY FSB
		STREET 2:		500 DELAWARE AVE, FL 11TH
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801
		BUSINESS PHONE:		213-441-2679

	MAIL ADDRESS:	
		STREET 1:		WILMINGTON SAVINGS FUND SOCIETY FSB
		STREET 2:		500 DELAWARE AVE, FL 11TH
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002050526</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>09/12/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001533998</issuerCik>
<issuerName>DarioHealth Corp.</issuerName>
<issuerCusip>23725P209</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>322 W, 57th Street, # 33B</com:street1>
<com:city>New York</com:city>
<com:stateOrCountry>NY</com:stateOrCountry>
<com:zipCode>10019</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Titan Trust 2024 I</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>2500100</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>2500100</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2500100</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>7.69</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>Row 5, Row 7 and Row 9 represent 2,500,100 shares of common stock of the Issuer issuable under a warrant dated February 15, 2024 exercisable within 60 days after September 12, 2024 that is directly held by the Reporting Person.  On November 14, 2024, 2,499,828 shares were issued to the Reporting Person by the Issuer pursuant to a cashless exercise of such warrant.&#13;
The percentage ownership reported in Row 11 was calculated based on a denominator that is the sum of 30,028,280 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuers Quarterly Report on Form 10-Q for the quarter ended June 30,2024 filed with the Securities and Exchange Commission (SEC) on August 8, 2024, plus the 2,500,100 shares reported hereby in Rows 5, 7 and 9.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>DarioHealth Corp.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>322 W, 57th Street, # 33B, New York, New York, 10019</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Titan Trust 2024 I</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>c/o WhiteHawk Capital Partners LP, as Administrator&#13;
11601 Wilshire Blvd., Suite 1980, Los Angeles, CA, 90025</principalBusinessOfficeOrResidenceAddress>
<citizenship>Titan Trust 2024 I is a Delaware statutory trust organized under the laws of the State of Delaware.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>2,500,100 shares of Common Stock of the Issuer. WhiteHawk Capital Partners LP ("WhiteHawk"), as the Administrator of Titan Trust 2024 I pursuant to a Trust Agreement dated February 15, 2024, may be deemed to beneficially own the securities reported herein. The filing of this Schedule 13G shall not be construed as an admission that WhiteHawk is, for the purposes of sections 13(d) or 13(g) of the Act, the beneficial owner of any securities covered hereby.</amountBeneficiallyOwned>
<classPercent>7.69</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>2,500,100</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>2,500,100</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Titan Trust 2024 I</reportingPersonName>
<signatureDetails>
<signature>By: WhiteHawk Capital Partners LP, its Administrator /s/ Robert Louzan</signature>
<title>Robert Louzan/Managing Partner</title>
<date>01/08/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
